Currently out of the existing stock ratings of Geulah Livshits, 267 are a BUY (97.8%), 6 are a HOLD (2.2%).

Geulah Livshits

Work Performance Price Targets & Ratings Chart

Analyst Geulah Livshits, currently employed at CHARDAN CAPITAL, carries an average stock price target met ratio of 31.93% that have a potential upside of 53% achieved within 165 days.

Geulah Livshits’s has documented 479 price targets and ratings displayed on 37 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on RCKT, Rocket Pharmaceuticals at 01-Sep-2026.

Wall Street Analyst Geulah Livshits

Analyst best performing recommendations are on PDSB (PDS BIOTECHNOLOGY CORP).
The best stock recommendation documented was for PDSB (PDS BIOTECHNOLOGY CORP) at 5/20/2021. The price target of $11 was fulfilled within 7 days with a profit of $3.73 (51.31%) receiving and performance score of 73.3.

Average potential price target upside

of $59.17 (9.41%) on MRNA (MODERNA).
of $52.15 (46.5%) on KRYS (KRYSTAL BIOTECH).
of $25.9 (100.13%) on NTLA (INTELLIA THERAPEUTICS).

CRSP Crispr Therapeutics AG EDIT Editas Medicine IOVA Iovance Biotherapeutics MRNA Moderna NTLA Intellia Therapeutics RCKT Rocket Pharmaceuticals RGNX Regenxbio KRYS Krystal Biotech SLDB Solid Biosciences LLC TSHA Taysha Gene Therapies VYGR Voyager Therapeutics FIXX Homology Medicines IMTX Immatics NV LOGC LogicBio Therapeutics TNYA Tenaya Therapeutics VINC Vincerx Pharma PRVB Provention Bio CABA Cabaletta Bio MGTX MeiraGTx Holdings PLC PASG Passage Bio SQZ Sqz Biotechnologies Co ACHL Achilles Therapeutics PLC ADR IMNM Immunome IMRX Immuneering Corp IPSC Century Therapeutics FDMT 4D Molecular Therapeutics CRGX CARGO Therapeutics, Common Stock LXEO Lexeo Therapeutics, Common Stock MGX Metagenomi, Common Stock SNTI Senti Biosciences ACH Aluminum Corp of China Ltd ADR PR Permian Resources PRME Prime Medicine, Common Stock RC Ready Capital Corp RCOR Renovacor VBLT Vascular Biogenics Ltd PDSB PDS Biotechnology Corp

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Gil Blum (NEEDHAM)

Buy Since 16-Feb-2022

$82

$26.21 (46.98%)

$82

8 days ago
(31-Aug-2026)

8/28 (28.57%)

$25.02 (43.91%)

214

1.09

Yigal Nochomovitz (CITI)

Buy Since 18-Apr-2024

$88

$32.21 (57.73%)

$82

1 months 4 days ago
(04-Aug-2026)

10/20 (50%)

$34.93 (65.82%)

160

6.83

Terence Flynn (MORGAN STANLEY)

Hold Since 11-Jun-2026

$60

$4.21 (7.55%)

$32

2 months 28 days ago
(11-Jun-2026)

9/9 (100%)

$9.77 (19.45%)

229

2.96

Edward Tenthoff (PIPER SANDLER)

Buy Since 17-Jan-2018

$110

$54.21 (97.17%)

$105

5 months 22 days ago
(17-Mar-2026)

27/36 (75%)

$59.91 (119.60%)

235

6.44

Geulah Livshits (CHARDAN CAPITAL)

Buy Since 28-Oct-2019

$76

$20.21 (36.23%)

$74

6 months 22 days ago
(17-Feb-2026)

2/16 (12.5%)

$22.83 (42.94%)

1.5

Show more analysts

Please expand the browser size to see the chart

Which stock is Geulah Livshits most bullish on?

Potential upside of $17.26 has been obtained for NTLA (INTELLIA THERAPEUTICS)

Which stock is Geulah Livshits most reserved on?

Potential downside of $0.77 has been obtained for EDIT (EDITAS MEDICINE)

What Year was the first public recommendation made by Geulah Livshits?

On 2019